Rubis S.A.

Rubis is a holding company based in France. Co., through its subsidiaries, is engaged in the bulk import, production or distribution process, and storage of petroleum products in Europe, the Caribbean, and Africa. Co. operates bulk liquid storage facilities for petroleum products, chemicals, fertilizers, edible oils and molasses, and foodstuffs, as well as distributes butane, propane, and petroleum products in wholesale and retail. Co.'s customers primarily include hypermarkets and supermarkets; oil companies; chemists; and traders and intermediaries of fuel, oil or gas, manures, and other liquids.
  • TickerRUI
  • ISINFR0013269123
  • ExchangeEuronext Paris
  • SectorGas, Water & Multi-utilities
  • CountryFrance
Emmanuel Matot ...
  • Marc Lavaud

Rubis : Un derating exagéré

Le modèle économique de Rubis, qui a fait ses preuves historiquement, ne peut être remis en cause par la crise de la COVID. Le derating massif du titre depuis le début de l’année nous apparaît exagéré, y compris en intégrant les incertitudes ESG long terme. Nous réitérons notre opinion Achat avec un OC ramené à 40 € vs 50 €. - >Le distributeur de produits pétroliers n’est pas asymptomatique à l’épidémie COVID-19 - Contrairement aux attentes initiales et à l’historique ...

Emmanuel Matot ...
  • Marc Lavaud

Rubis : Excessive de-rating

Rubis' business model, which has proved its worth over the years, cannot be thrown into disarray by the COVID-19 crisis. The massive de-rating of the stock since the beginning of the year seems excessive to us, even when including long-term ESG uncertainties. We reiterate our Buy recommendation with a TP reduced to €40 vs €50. - >The petroleum products distributor is not asymptomatic to the COVID-19 epidemic - Contrary to initial expectations, Rubis was hit by the COVI...

Rubis: 1 director sold

A director at Rubis sold 2,700 shares at 34.842EUR and the significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board members a...

Anis Zgaya ...
  • Bruno Cavalier
  • Emmanuel Matot
  • Fehmi Ben Naamane
  • Jean Sassus
  • Johanna Jourdain
  • Louis Boujard, CFA
  • Martial Descoutures
  • Oussema Denguir
  • Philippe Ourpatian
  • Sebastien Malafosse
  • Steven Gould
  • Syrine Kabboura
  • Thomas Renaud

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 18/09/2020

...

Anis Zgaya ...
  • Emmanuel Matot
  • Fehmi Ben Naamane
  • Jean Sassus
  • Johanna Jourdain
  • Louis Boujard, CFA
  • Martial Descoutures
  • Oussema Denguir
  • Philippe Ourpatian
  • Sebastien Malafosse
  • Steven Gould
  • Syrine Kabboura
  • Thomas Renaud

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 09/18/2020

...

Jérôme VINERIER

Analyse court terme - RUBIS : La tendance de fond est clairement orientée à la baisse.

La tendance de fond est clairement orientée à la baisse. Le MACD est négatif, il confirme cette tendance. La reprise est une consolidation qui va buter sur 46,10 € prochainement. Le prochain objectif est à 42,40 €, puis 40,20 €. Le franchissement de 52,10 € remettrait en cause la suite de la baisse.

Jérôme VINERIER

Short term view - RUBIS : The background trend is clearly bearish.

The background trend is clearly bearish. The negative MACD confirms the trend. The rise is a consolidation that will soon bump against the level at €46.10. The next target is at €42.40, then €40.20. Passing €52.10 would question the continuation of the fall.

Jérôme VINERIER

Short term view - RUBIS : Falling prices.

The background trend is clearly bearish. Prices are falling again, but the movement has become hesitant. The next support is at €42.40. The background trend would be questioned should prices rise above €52.10.

Jérôme VINERIER

Analyse court terme - RUBIS : Les prix baissent.

La tendance de fond est clairement orientée à la baisse. Les prix baissent à nouveau, mais le mouvement est devenu hésitant. Le prochain support est à 42,40 €. La tendance de fond serait remise en cause en cas de franchissement de 52,10 €.

Valérie GASTALDY

Medium term view - RUBIS : The trend is uncertain.

The trend is uncertain. Prices are falling and they may accelerate to the downside. A new bearish trend is attempting to emerge.

Rubis: 1 director sold

A director at Rubis sold 2,700 shares at 34.842EUR and the significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board members a...

Emmanuel Matot ...
  • Marc Lavaud

Rubis : Un derating exagéré

Le modèle économique de Rubis, qui a fait ses preuves historiquement, ne peut être remis en cause par la crise de la COVID. Le derating massif du titre depuis le début de l’année nous apparaît exagéré, y compris en intégrant les incertitudes ESG long terme. Nous réitérons notre opinion Achat avec un OC ramené à 40 € vs 50 €. - >Le distributeur de produits pétroliers n’est pas asymptomatique à l’épidémie COVID-19 - Contrairement aux attentes initiales et à l’historique ...

Emmanuel Matot ...
  • Marc Lavaud

Rubis : Excessive de-rating

Rubis' business model, which has proved its worth over the years, cannot be thrown into disarray by the COVID-19 crisis. The massive de-rating of the stock since the beginning of the year seems excessive to us, even when including long-term ESG uncertainties. We reiterate our Buy recommendation with a TP reduced to €40 vs €50. - >The petroleum products distributor is not asymptomatic to the COVID-19 epidemic - Contrary to initial expectations, Rubis was hit by the COVI...

Anis Zgaya ...
  • Bruno Cavalier
  • Emmanuel Matot
  • Fehmi Ben Naamane
  • Jean Sassus
  • Johanna Jourdain
  • Louis Boujard, CFA
  • Martial Descoutures
  • Oussema Denguir
  • Philippe Ourpatian
  • Sebastien Malafosse
  • Steven Gould
  • Syrine Kabboura
  • Thomas Renaud

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 18/09/2020

...

Anis Zgaya ...
  • Emmanuel Matot
  • Fehmi Ben Naamane
  • Jean Sassus
  • Johanna Jourdain
  • Louis Boujard, CFA
  • Martial Descoutures
  • Oussema Denguir
  • Philippe Ourpatian
  • Sebastien Malafosse
  • Steven Gould
  • Syrine Kabboura
  • Thomas Renaud

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 09/18/2020

...

Emmanuel Matot ...
  • Thomas Renaud

Rubis : Slump in volumes mitigated by unit margins and S&S

>The COVID crisis did much damage to H1 earnings but no worse than expected - Rubis released its H1 results yesterday evening. Earnings were down sharply due to the COVID crisis (net profit = -11% with -30% at constant scope) but came in ahead of our forecasts (which were particularly cautious).At constant scope, we note above all the fall in earnings in the energy division (underlying operating profit = -29% to € 130m), which was due to a collapse, as expected, ...

Jehanne Leroy

Rubis - Assemblée générale des actionnaires du 11 juin 2019

Nous regrettons que, malgré nos demandes de 2016, la société ne propose toujours pas de modification de son article 56 relatif au dividende statutaire des associés commandités. En effet, selon Proxinvest, la formule de l’article 56 n’empêche pas un scénario d’enrichissement des associés commandités et d’appauvrissement des actionnaires sur plusieurs années et ce dividende statutaire d'associé commandité peut avoir de potentiels effets pervers (effet de cliquet et prélèvements excessifs par rapport au risque supporté).En 2017 par exemple, le cours a augmenté de 51% et le dividende statutaire a ...

Sven Edelfelt ...
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 07/22/2020

...

Sven Edelfelt ...
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 22/07/2020

...

Alain William ...
  • Alexandre Iatrides
  • Alfred Glaser
  • Benoit Valleaux
  • Delphine Brault
  • Emmanuel Matot
  • Geoffroy Michalet
  • Harald Eggeling
  • Jean Sassus
  • Laurence Hofmann
  • Louis Boujard, CFA
  • Martial Descoutures
  • Michael Foundoukidis
  • Olfa Taamallah
  • Philippe Ourpatian
  • Roland Pfaender,MBA,CFA,CCRA
  • Sebastien Malafosse
  • Steven Gould
  • Sven Edelfelt
  • Virginie Rousseau
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 05/07/2020

...

Alain William ...
  • Alexandre Iatrides
  • Alfred Glaser
  • Benoit Valleaux
  • Delphine Brault
  • Emmanuel Matot
  • Geoffroy Michalet
  • Harald Eggeling
  • Jean Sassus
  • Laurence Hofmann
  • Louis Boujard, CFA
  • Martial Descoutures
  • Michael Foundoukidis
  • Olfa Taamallah
  • Philippe Ourpatian
  • Roland Pfaender,MBA,CFA,CCRA
  • Sebastien Malafosse
  • Steven Gould
  • Sven Edelfelt
  • Virginie Rousseau
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 07/05/2020

...

Ahmed Ben Salem ...
  • Antoine Boivin-Champeaux
  • Benoit Valleaux
  • Bruno Cavalier
  • Emmanuel Matot
  • Jerôme Bodin
  • Johanna Jourdain
  • Laurence Hofmann
  • Martial Descoutures
  • Matthias Desmarais
  • Pierre Tegner
  • Roland Pfaender,MBA,CFA,CCRA
  • Sebastien Malafosse
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 04/14/2020

We held a conference call last Wednesday with Stéphane Bancel, Moderna’s CEO. We were able to discuss the next stages involved in the development of its COVID-19 vaccine which, it is worth noting, is the first to be tested in humans. Considering the progress being made and the prospect of its vaccine reaching the market within just a few months, we have now decided to factor this asset into our valuation model. We have thus adjusted our valuation from $ 32 to $ 37 and reiterate our Bu...

A double requalification allows RUBIS to improve to Slightly Positive

RUBIS (FR), a company active in the Oil Equipment & Services industry, has received a double requalification by the independent financial analyst theScreener. Its fundamental valuation is now 3 out of 4 stars while its market behaviour can be considered as defensive. theScreener believes that the gain of a star(s) and an improvement in the market risk perception allows upgrading the general evaluation to Slightly Positive. As of the analysis date May 22, 2020, the closing price was EUR 42.18 and its potential was estimated at EUR 47.48.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch